Clinical Perspectives on Managing ALK Inhibitor Adverse Events
Panelists discuss how they manage adverse events associated with ALK inhibitors, comparing safety profiles and addressing unique patient concerns.
Using a real patient case, the panel discusses the adverse effects associated with ALK inhibitors and how they differ across agents. For example, lorlatinib is effective but has unique adverse events like cognitive changes and hyperlipidemia, while alectinib is typically more tolerable but may cause constipation or fatigue.
Management strategies include close monitoring during the first few weeks, early intervention, and patient education. The case example highlights the importance of addressing quality-of-life concerns, such as maintaining cognitive function, especially in working patients with demanding roles.
Nurses and advanced practice providers must balance treatment efficacy with adverse effect management. Empowering patients to report symptoms early and adjusting medications or supportive therapies when needed ensures better adherence and minimizes the need for treatment discontinuation.
